Shore Capital Restated “Buy” Rating For Sirius Minerals (LON:SXX); Rigel Pharmaceuticals (RIGL)’s Sentiment Is 1.39

February 15, 2018 - By Marguerite Chambers

Shore Capital reconfirmed their “Buy” rating on shares of Sirius Minerals (LON:SXX) in an analyst note shared with investors on Wednesday, 14 February.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $556.67 million. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

The stock increased 3.54% or $0.13 during the last trading session, reaching $3.8. About 931,746 shares traded. Rigel Pharmaceuticals, Inc. (RIGL) has risen 4.56% since February 15, 2017 and is uptrending. It has underperformed by 12.14% the S&P500.

Ratings analysis reveals 100% of Rigel Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Rigel Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $7.0 while the high is $11.0. The stock’s average target of $9 is 136.84% above today’s ($3.8) share price. RIGL was included in 2 notes of analysts from August 30, 2016. H.C. Wainwright maintained it with “Buy” rating and $7.0 target in Wednesday, August 31 report. The company was maintained on Tuesday, August 30 by Piper Jaffray.

Great Point Partners Llc holds 4.5% of its portfolio in Rigel Pharmaceuticals, Inc. for 9.11 million shares. Sio Capital Management Llc owns 1.56 million shares or 2.06% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 0.76% invested in the company for 2.35 million shares. The California-based Dafna Capital Management Llc has invested 0.7% in the stock. Ghost Tree Capital Llc, a New York-based fund reported 1.10 million shares.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on March, 6. They expect $-0.13 earnings per share, up 18.75% or $0.03 from last year’s $-0.16 per share. After $-0.14 actual earnings per share reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -7.14% EPS growth.

Sirius Minerals Plc, a fertilizer development company, engages in the evaluation and exploration of resource properties in the United Kingdom. The company has market cap of 1.06 billion GBP. The firm explores for polyhalite resources. It currently has negative earnings. The Company’s North Yorkshire polyhalite project is located in the United Kingdom.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts